騰盛博藥-B:2023年度報告
Tengsheng Pharmaceutical-B (02137) granted a total of 5.752,500 share options and 821,500 restricted share units
Tengsheng Pharmaceutical-B (02137) issued an announcement. On March 28, 2024, the company purchased shares in accordance with 2023...
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Tengsheng Pharmaceutical-B (02137.HK) will actively seek external cooperation with R&D expenditure of 403 million yuan in 2023
Gelonghui, March 22 | Tengsheng Pharmaceutical-B (02137.HK) announced that for the year ended December 31, 2023, other revenue was RMB 163.7 million, an increase of RMB 55.8 million or 51.7% compared with RMB 107.9 million for the year ended December 31, 2022. This was mainly due to an increase in interest income of RMB 70.8 million due to rising interest rates on US dollar and Hong Kong dollar time deposits. This increase was partially offset by a reduction in revenue recognized by the Chinese government subsidy. For the year ended December 31, 2023, R&D expenditure was for the people
BRII-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Tengsheng Pharmaceutical-B (02137.HK) will hold a board meeting on March 22 to approve the annual results
Gelonghui March 11 | Tengsheng Pharmaceutical-B (02137.HK) issued an announcement. The company will hold a board meeting on March 22, 2024 to review and approve the company's annual results and announcements for the year ended December 31, 2023.
BRII-B: DATE OF BOARD MEETING
After falling nearly 45% in two days and excluding Hong Kong Stock Connect, Tengsheng Pharmaceutical-B (02137) was seriously injured?
As the stock with the worst decline on the list, the reason behind the successive sharp declines of Tengsheng Pharmaceutical-B is not just an appearance on paper.
Changes in Hong Kong stocks | Tengsheng Pharmaceutical-B (02137) fell more than 26%, and its stock price hit a new low and was removed from the Hong Kong Stock Connect list
The Zhitong Finance App learned that Tengsheng Pharmaceutical-B (02137) fell by more than 26%, and the intraday low of HK$1.22 hit a new low since listing. As of press release, it decreased by 26.47% to HK$1.25, with a turnover of HK$20.313,900. According to the news, according to the Hong Kong Stock Exchange and the Hong Kong Stock Exchange's adjustment announcements issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, Tengsheng Pharmaceuticals has been removed from the Hong Kong Stock Connect list, which will take effect today. According to reports, Tengsheng Pharmaceutical announced the discontinuation of production of the COVID-19 neutralizing antibody last year. It is its only commercial product, contributing all of its revenue in 2022. In 2022, the company lost 484 million yuan
Express News | Shenzhen Stock Exchange: Changes to the list of Hong Kong Stock Exchange securities under the Shenzhen-Hong Kong Stock Connect
Guojin Securities: Chronic Hepatitis B Cure Track has broad potential market space and continues to recommend companies that deploy long-acting interferons and related innovative drugs
The chronic hepatitis B cure track is one of the tracks that the trip continues to be optimistic about and recommended. Clinical cure for chronic hepatitis B has now entered a new stage from early exploration to international recognition to rapid and in-depth development.
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Changes in Hong Kong stocks | Tengsheng Pharmaceutical-B (02137) rose more than 9% intraday and recently acquired HBV Pharmaceuticals' intellectual property rights and cancer vaccine development rights in the Asia-Pacific region
Tengsheng Pharmaceutical-B (02137) rose more than 9% in the intraday period. As of press release, it was up 5.14% to HK$1.84, with a turnover of HK$4.926,300.
Opinion | Hang Seng Index quarterly inspection results announced, which companies are expected to become the Hong Kong Stock Exchange Index?
After the market on February 16, 2024, Hang Seng Indices announced the results of its regular semi-annual index adjustments (the review ends on December 31, 2023, and is generally announced within 8 weeks after the inspection date). The scope of this adjustment covers the main flagship indices of Hong Kong stocks, such as the Hang Seng, the State-owned Enterprises Index, and the Hang Seng Technology Index; in addition, the Hang Seng Composite Index, which directly determines the scope of investment in Hong Kong Stock Connect, has also been adjusted.
VBI Vaccines: Received $2.5 M of Consideration Upon Signing of Definitive Documents and Expect to Receive Up to an Additional $30.5M of Consideration, Subject to Achievement of Certain Activities, With a Target Completion Date of June 30 >VBIV
VBI Vaccines: Received $2.5 M of Consideration Upon Signing of Definitive Documents and Expect to Receive Up to an Additional $30.5M of Consideration, Subject to Achievement of Certain Activities, Wit
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement With Brii Biosciences
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement With Brii Biosciences
Brii Biosciences to Buy Rights to Hepatitis B Vaccine From VBI
Brii Biosciences (HKG:2137) will buy all the rights, title, and interest related to the BRII-179 hepatitis B vaccine from VBI Vaccines and subsidiaries Variation Biotechnologies and SciVac for a maxim
Brii Biosciences: Upon Meeting Specific Conditions, the Note Will Increase to $10M, Securing All of VBI's Intellectual Properties for BRII-179, With Associated Payments Also Eliminated
Brii Biosciences: Upon Meeting Specific Conditions, the Note Will Increase to $10M, Securing All of VBI's Intellectual Properties for BRII-179, With Associated Payments Also Eliminated
Brii Biosciences Will Also Take Control of VBI's Rehovot-based Manufacturing Facilities for BRII-179 and PreHevbrio/PreHevbri for $10M Cash on or After June 30
Brii Biosciences Will Also Take Control of VBI's Rehovot-based Manufacturing Facilities for BRII-179 and PreHevbrio/PreHevbri for $10M Cash on or After June 30
No Data